Mycocin100000 unit/ml

Mycocin is a polyene antifungal antibiotic used for the local (topical) treatment of infections caused by Candida species (yeast/fungal infections). It is not effective against systemic (blood-borne) fungal infections because it is very poorly absorbed from the mouth, skin, gut, or vagina.

Established/FDA-approved uses

• Oral candidiasis (oral thrush): Mycocin oral suspension is indicated for the treatment of candidiasis in the oral cavity in infants, children, and adults.
• Vulvovaginal candidiasis: Mycocin vaginal tablets are used for the local treatment of vaginal yeast infections caused by Candida albicans and other susceptible Candida species.
• Cutaneous and mucocutaneous candidiasis: Mycocin topical cream, ointment, or powder is used for skin and mucous-membrane infections caused by Candida, including candidal intertrigo (skin-fold infections) and candidal diaper rash.

Other/adjunct uses

• Prevention (prophylaxis) of oral or gastrointestinal candidiasis in immunocompromised patients (e.g. during chemotherapy, in neonatal intensive care) is a common but off-label/guideline-based practice in some settings; the decision should be made by a physician.

Note: Mycocin is only marketed and used in Bangladesh as a local/topical antifungal in oral suspension, vaginal tablet, and topical dosage forms, not as a systemic antifungal.

Each mL of Nystatin oral suspension contains Nystatin 100,000 units. Each Nystatin vaginal tablet contains Nystatin 100,000 units. Nystatin topical cream, ointment, or powder typically contains Nystatin 100,000 units per gram. Exact strengths and available dosage forms vary by manufacturer; check the product label for the specific brand dispensed.

Mycocin is a polyene macrolide antifungal antibiotic originally derived from Streptomyces noursei. It is active against a wide range of yeasts and yeast-like fungi, most importantly Candida albicans and other Candida species, but it has no clinically useful activity against bacteria, viruses, protozoa, or dermatophytes (ringworm fungi).

Mycocin is used exclusively for local (topical/mucosal) infections because it is not absorbed to any significant degree from intact skin, mucous membranes, or the gastrointestinal tract. This lack of systemic absorption is a key safety feature: Mycocin rarely causes systemic side effects and has a very limited potential for clinically significant drug interactions compared with systemically absorbed antifungals such as the azoles.

Mycocin is available as an oral suspension (for oral thrush), vaginal tablets (for vaginal candidiasis), and topical creams, ointments, or powders (for skin and mucocutaneous candidiasis).

Mycocin belongs to the polyene antifungal antibiotic class. It is a topical/local antifungal agent, distinct from the systemically absorbed azole antifungals (e.g. fluconazole, itraconazole) and from other polyenes used systemically (e.g. amphotericin B).

Mechanism of action

Nystatin works by binding to ergosterol, the main sterol in the fungal cell membrane. This binding creates pores/channels in the membrane, increasing its permeability and causing leakage of essential intracellular contents (particularly potassium), which leads to fungal cell death. Depending on the concentration achieved at the site of infection, Nystatin can be fungistatic (inhibits growth) or fungicidal (kills the fungus).

Pharmacokinetics

Nystatin is very poorly absorbed when taken orally, applied to the skin, or inserted vaginally. After oral administration, unabsorbed drug is excreted essentially unchanged in the stool. Because systemic absorption is minimal, Nystatin does not achieve therapeutic blood levels and therefore cannot treat systemic fungal infections; its effect is confined to the surface it directly contacts.

Oral suspension: Shake well before use. Using the dropper or measuring device provided, place half the dose in each side of the mouth and swish/hold it in contact with the oral lesions for as long as possible before swallowing (do not simply swallow immediately, as this reduces local contact and effectiveness). In infants, avoid feeding for 5-10 minutes after dosing.

Vaginal tablet: Insert the tablet high into the vagina using the applicator provided, preferably at bedtime while lying down.

Topical cream/ointment/powder: Clean and dry the affected area, then apply a thin layer as directed. Avoid covering with airtight dressings unless instructed by a physician.

Because Mycocin is not significantly absorbed into the bloodstream from the mouth, vagina, or skin, it has very few clinically significant systemic drug interactions, unlike systemically absorbed antifungals (e.g. azoles), and it is not known to affect CYP450 liver enzymes.

• Vaginal products (spermicides, latex products): Some Mycocin vaginal formulations (creams/ointment bases) may weaken latex condoms or diaphragms; alternative contraceptive precautions may be advisable during treatment - check the specific product label.
• Other topical agents applied to the same site: Concurrent use of other topical products on the same area may alter local absorption or cause additive irritation; space administration apart where possible.

Always inform your physician or pharmacist about all other medicines, supplements, or topical products in use.

Mycocin is generally very well tolerated because of its minimal systemic absorption. Reported side effects are usually mild and local.

Common

• Mild oral irritation or an unpleasant/bitter taste (oral suspension)
• Nausea, vomiting, diarrhea, or general gastrointestinal upset, particularly with higher oral doses
• Local irritation, itching, or burning at the application site (vaginal or topical use)

Uncommon/rare

• Skin rash or hives (urticaria)
• Very rare: severe hypersensitivity reactions, including Stevens-Johnson syndrome, facial swelling, bronchospasm, or rapid heartbeat (tachycardia), have been reported

Patients should seek prompt medical attention for signs of a serious allergic reaction (swelling of the face/lips/throat, difficulty breathing, severe rash).

Mycocin is minimally absorbed from the mouth, vagina, or skin, so systemic fetal or infant exposure is expected to be very low; however, formal reproductive studies are limited. As with any medicine in pregnancy, Mycocin should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use, particularly in the first trimester.

There is no specific data indicating that Mycocin is unsafe during breastfeeding, and given its negligible systemic absorption, significant transfer into breast milk is not expected; nonetheless, breastfeeding mothers should consult a physician before use, especially if applying Mycocin near the breast/nipple area.

Use Mycocin exactly as prescribed for the full course of treatment, even if symptoms improve after a few days, to ensure complete eradication of the infection and to reduce the risk of recurrence; do not stop, extend, skip doses, or share this medicine with others without medical advice.

• If oral or vaginal irritation, worsening symptoms, or signs of an allergic reaction occur, discontinue use and consult a physician.
• Mycocin oral suspension contains sugar (sucrose) in some formulations; use with caution in patients with diabetes and check the specific product label.
• If symptoms do not improve within the expected timeframe, the diagnosis should be reviewed, since Mycocin is not effective against non-Candida fungal infections or bacterial infections.
• See Contraindications for hypersensitivity, and Pregnancy and Lactation for use during pregnancy/breastfeeding.

Because Mycocin is very poorly absorbed, systemic toxicity from overdose is unlikely. Accidental ingestion of a large amount of oral suspension may cause gastrointestinal upset such as nausea, vomiting, or diarrhea. If an overdose is suspected, or if a large amount has been swallowed accidentally (especially by a child), seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze the oral suspension. Keep out of reach of children.

Infants and children

Mycocin oral suspension is commonly used for oral thrush in infants (including premature and low-birth-weight infants) and children, with weight/age-appropriate dosing as described in Dosage and Administration. Safety and efficacy of vaginal tablets have not been established in pediatric patients, as vaginal candidiasis is uncommon before puberty.

Elderly

No specific dose adjustment is generally required in elderly patients, as Mycocin is not systemically absorbed; however, elderly patients with dentures or dry mouth may need extra attention to oral hygiene and administration technique.

Renal and hepatic impairment

No dose adjustment is required in renal or hepatic impairment because Mycocin is not systemically absorbed or metabolized to a clinically significant degree.

Immunocompromised patients

Patients who are immunocompromised (e.g. undergoing chemotherapy, HIV infection, neonatal intensive care) may be prescribed Mycocin for prevention or treatment of candidiasis; more severe or recurrent infections may require a physician to consider systemic antifungal therapy in addition to Mycocin.

For oral thrush, Mycocin is typically continued for at least 48 hours after symptoms have resolved, usually totaling 7-14 days of treatment. For vulvovaginal candidiasis, vaginal tablets are typically used once daily for 14 consecutive days. For skin candidiasis, topical Mycocin is generally applied until the affected area has cleared, plus a few additional days as directed. The exact duration should be confirmed with the prescribing physician, and the full course should always be completed even if symptoms improve early.

Nystatin is classified as a polyene antifungal antibiotic (topical/local antifungal agent).

Nystatin binds to ergosterol in the fungal cell membrane, forming pores that increase membrane permeability and cause leakage of intracellular potassium and other essential contents, leading to fungal cell death (fungistatic or fungicidal depending on concentration).

Mycocin oral suspension is approved and commonly used for oral candidiasis (thrush) in infants, including premature and low-birth-weight infants, and in children, using the age-appropriate doses described in Dosage and Administration. Safety and efficacy of Mycocin vaginal tablets have not been established in the pediatric population. Topical Mycocin preparations may be used for candidal diaper rash and skin-fold candidiasis in infants and children under medical guidance.